Trastuzumab Deruxtecan + SRS for Breast Cancer with Brain Metastases

This trial explores a new treatment for HER-2 positive breast cancer that has spread to the brain. Researchers aim to determine if combining Trastuzumab Deruxtecan, a cancer-fighting drug, with stereotactic radiosurgery (SRS), a targeted radiation method, can better control these brain metastases. Individuals recently diagnosed with up to 10 small brain metastases and HER-2 positive breast cancer may be suitable candidates for this trial. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative combination therapy.

The trial does not specify if you need to stop taking your current medications, but it does prohibit the use of anthracyclines while participating. It's best to discuss your specific medications with the trial team.

Research has shown that combining Trastuzumab Deruxtecan (T-DXd) with stereotactic radiosurgery (SRS) is generally well-tolerated by patients with HER2-positive breast cancer that has spread to the brain. This treatment combination has improved control over brain metastases.

However, limited information exists on the safety of using T-DXd with SRS. Previous studies reported side effects, such as lung problems like interstitial lung disease (ILD) and pneumonitis, which can occur at different times.

Trastuzumab Deruxtecan is unique because it combines an antibody specifically targeting HER2-positive cancer cells with a potent chemotherapy drug, delivering treatment directly to where it's needed most. This is different from standard treatments like whole brain radiation or traditional chemotherapy, which can affect healthy cells and cause significant side effects. Researchers are excited about this treatment because it offers the potential for a more precise and effective attack on breast cancer cells that have spread to the brain, with possibly fewer side effects compared to traditional treatments.

Research has shown that Trastuzumab Deruxtecan (T-DXd) holds promise for treating HER2-positive breast cancer that has spread to the brain. One study significantly helped 73.3% of patients with brain metastases using T-DXd. Another study found T-DXd very effective in real-world settings, reducing brain tumors in 71% of women with metastatic breast cancer. In this trial, all participants will receive both T-DXd and Stereotactic Radiosurgery (SRS) to evaluate safety and determine an appropriate dose. These findings suggest that T-DXd could effectively control breast cancer that spreads to the brain.⁶⁷⁸⁹¹⁰